Abstract
Raynaud’s phenomenon is a common disorder with vasospasm of the digital arteries causing pallor with cyanosis and/or rubor. It can be primary (idiopathic), where it is not associated with other diseases, or secondary to several diseases or conditions, including connective tissue diseases, such as scleroderma and systemic lupus erythematosus. Raynaud’s is often mild enough to not require treatment; however, with secondary Raynaud’s there is not only vasospasm but also fixed blood vessel defects so the ischaemia can be more severe. Complications can include digital ulcers and could, rarely, lead to amputation. Treatment is often non-pharmacological including avoiding cold and smoking cessation. Calcium channel antagonists, such as nifedipine, are often considered when treatment is needed; however, adverse effects of these drugs can include hypotension, vasodilatation, peripheral oedema and headaches. Other treatments have been studied in randomised, controlled trials including classes of drugs, such as angiotensin II inhibitors, selective serotonin reuptake inhibitors, phosphodiesterase-5 inhibitors (e.g. sildenafil), nitrates (topical or oral; the latter can be limited by adverse effects, such as flushing, headache and hypotension), and for more serious Raynaud’s or its complications prostacyclin agonists may be used. There are two large studies that demonstrate that endothelin receptor blockade with bosentan can reduce the number of new digital ulcers in scleroderma patients. However, it does not affect the healing period
Thus, Raynaud’s is common and often requires non-pharmacological treatment. When secondary Raynaud’s is suspected, such as Raynaud’s with an older age at onset or other features of connective tissue disease, then an appropriate history, physical examination and laboratory tests may be indicated to reach an appropriate diagnosis. There have been advances in pharmacological treatment, but some of the treatments are limited by adverse effects.
Similar content being viewed by others
References
Pope J. Raynaud’s phenomenon (primary). Clin Evidence 2003 Jun; 9: 1339–48
Herrick A. Pathogenesis of Raynaud’s phenomenon. Rheumatology (Oxford) 2005 May; 44(5): 587–96
White CR, Haidekker MA, Stevens HY, et al. Extracellular signal-regulated kinase activation and endothelin-1 production in human endothelial cells exposed to vibration. J Physiol 2004 Mar l; 555 (Pt 2): 565–72
Pistorius MA, Planchon B, Schott JJ, et al. Heredity and genetic aspects of Raynaud’s disease. J Mal Vasc 2006 Feb; 31(1): 10–5
Boin F, Wigley FM. Understanding, assessing and treating Raynaud’s phenomenon. Curr Opin Rheumatol 2005 Nov; 17(6): 752–60
Herrick A. Treatment of Raynaud’s phenomenon: new insights and developments. Curr Rheumatol Rep 2003 Apr; 5(2): 168–74
Ohtsuka T, Tamura T, Yamakage A, et al. The predictive value of quantitative nailfold capillary microscopy in patients with undifferentiated connective tissue disease. Br J Dermatol 1998 Oct; 139(4): 622–9
Bergman R, Sharony L, Schapira D, et al. The handheld dermatoscope as a nail-fold capillaroscopic instrument. Arch Dermatol 2003 Aug; 139(8): 1027–30
Pope JE, Black C, Matucci-Cerinic M, et al. Functional correlates of reduction of digital ulcers by bosentan therapy in patients with systemic sclerosis (SSc). Arthritis Rheum 2006; 54 Suppl. 9: S740
Eliasson K, Danielson M, Hylander B, et al. Raynaud’s phenomenon caused by beta-receptor blocking drugs: improvement after treatment with a combined alpha- and beta-blocker. Acta Med Scand 1984; 215(4): 333–9
Brotzu G, Falchi S, Mannu B, et al. The importance of presynaptic beta receptors in Raynaud’s phenomenon. J Vasc Surg 1989 Jun; 9(6): 767–71
Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud’s phenomenon: a meta-analysis. Rheumatology (Oxford) 2005 Feb; 44: 145–50
Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999 Dec; 42(12): 2646–55
Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 2001 Sep; 40(9): 1038–43
Rustin MH, Almond NE, Beacham JA, et al. The effect of captopril on cutaneous blood flow in patients with primary Raynaud’s phenomenon. Br J Dermatol 1987 Dec; 117(6): 751–8
Teh LS, Manning J, Moore T, et al. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud’s phenomenon. Br J Rheumatol 1995 Jul; 34(7): 636–41
Franks AG. Topical glyceryl trinitrate as adjunctive treatment in Raynaud’s disease. Lancet 1982 Jan 9; 1(8263): 76–7
Fries R, Shariat K, von Wilmowsky H, et al. Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 2005 Nov 8; 112(19): 2980–5
DiGiacomo RA, Kremer JM, Shad DM. Fish-oil dietary supplementation in patients with Raynaud’s: a double-blind, controlled, prospective study. Am J Med 1989 Feb; 68(2): 158–64
Belch JJ, Shaw B, O’Dowd A, et al. Evening primrose oil (Efamol) in the treatment of Raynaud’s phenomenon: a double blind study. J Thromb Haemost 1985 Aug 30; 54(2): 490–4
Muir AH, Robb R, McLaren M, et al. The use of Ginkgo biloba in Raynaud’s disease: a double-blind placebo controlled trial. Vasc Med 2002; 7(4): 265–7
Appiah R, Hiller S, Caspary L, et al. Treatment of primary Raynaud’s syndrome with traditional Chinese acupuncture. J Intern Med 1997 Feb; 241(2): 119–24
Al-Awami M, Schillinger M, Maca T, et al. Low-level laser therapy treatment of primary and secondary Raynaud’s phenomenon. Vasa 2004 Feb; 33(1): 25–9
Ko GD, Berbrayer D. Effect of ceramic-impregnated ‘thermoflow’ gloves on patients with Raynaud’s syndrome: randomized, placebo-controlled study. Altern Med Rev 2002 Aug; 7(4): 328–35
Baron M. Personal communication of unpublished data from the Canadian Scleroderma Research Group (CSRG)
Wigley FM, Seibold JR, Wise RA, et al. Intravenous iloprost treatment of Raynaud’s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992 Sep; 19(9): 1407–14
Seibold JR, Matucci-Cerinic M, Denton CP, et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis. Ann Rheum Dis 2006; 65 Suppl. II: 90
Black C, Denton CP, Furst DE, et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis: open label extension to a double-blind trial. Ann Rheum Dis 2006; 65 Suppl. II: 384
Varga J. New hope for systemic sclerosis patients with digital ulcers. Curr Rheumatol Rep 2005 Apr; 7(2): 127–8
Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004 Dec; 50(12): 3985–93
Acknowledgements
The author would like to acknowledge that the paragraph on complementary and alternative treatments was contributed by Deanne Malenfant and that the manuscript was prepared by Gillian Ouimet. No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pope, J.E. The Diagnosis and Treatment of Raynaud’s Phenomenon. Drugs 67, 517–525 (2007). https://doi.org/10.2165/00003495-200767040-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200767040-00003